VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALNY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALNYAlnylam Pharmaceuticals, Inc.
$143.82$19.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALNYBalance Sheet

Alnylam Pharmaceuticals, Inc. (ALNY) Balance Sheet

24Y historyFree accessUpdated daily

Total debt has held near $1.3B after stepping down from $2.7B, and debt-to-equity fell from 84.26 in 2024Q3 to 0.35 in 2026Q3 as equity rebuilt to $3.6B, though the current ratio's decline from 3.13 to 2.48 suggests a narrowing liquidity cushion.

Income StatementBalance SheetCash FlowRatios

ALNY Balance Sheet

Annual statement

ALNY Balance Sheet

Alnylam Pharmaceuticals, Inc. (ALNY) balance sheet — 24-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02
Total Current Assets5.11B4.05B3.3B2.98B2.69B2.81B2.61B1.72B1.2B1.76B671.88M1.11B746.37M254.03M125.56M152.03M254.14M293.53M443.12M397.9M222.78M82.41M48.18M24.19M15.52M
Cash & Short-Term Investments3.59B2.91B2.69B2.44B2.19B2.44B1.87B1.54B1.08B1.69B626.8M1.08B696.69M245.87M122.81M146.4M233.13M281.4M430.39M389.95M217.26M80M46.05M23.19M15.48M
Cash Only1.75B1.66B966.43M812.69M866.39M819.98M496.58M547.18M420.15M645.36M193.62M180.9M75.18M53.17M51.41M70.23M74.6M137.47M191.79M105.16M127.95M15.76M20.27M23.19M15.48M
Short-Term Investments1.83B1.25B1.73B1.63B1.33B1.62B1.38B988.98M664.01M1.05B433.18M899.64M621.51M192.7M71.41M76.17M158.53M143.93M238.6M284.79M89.31M64.25M25.77M00
Accounts Receivable1.08B777.57M405.31M327.79M237.96M198.57M602.41M43.01M18.76M34M23.33M8.3M39.94M4.25M104K1.47M3.45M6.04M4.19M5.03M3.83M755K1.17M00
Days Sales Outstanding66.676.4265.865.4483.7285.85446.1471.4491.41138.03180.673.7288.3132.870.576.4712.5921.9415.936.0851.948.2199.74--
Inventory105.91M82.72M78.51M89.15M128.96M86.36M75.2M56.35M24.07M0000000-226.24M00000000
Days Inventory Outstanding29.6344.5988.62104.82278.83224.93351.67820.654.88K----------------
Other Current Assets0281.89M116.96M126.38M132.92M000000003.91M0001.94M3.87M0000373K19K
Total Non-Current Assets2.88B915.67M944.7M847.18M854.11M834.73M792.28M679.27M374.11M229.99M590.93M281.12M333.23M166.5M161.96M129.89M139.13M187.85M111.55M95.89M17.22M15.93M17.93M10.99M592K
Property, Plant & Equipment792.86M708.06M693.93M725.79M738.63M733.63M706.51M646.38M320.66M181.9M114.57M27.81M21.74M16.45M19.8M14.64M18.29M18.32M19.19M13.81M12.17M10.58M11.69M4.76M526K
Fixed Asset Turnover6.81x5.25x3.24x2.52x1.40x1.15x0.70x0.34x0.23x0.49x0.41x1.48x2.33x2.87x3.37x5.65x5.47x5.49x5.01x3.69x2.21x0.54x0.37x0.04x-
Goodwill0000000000000000000000000
Intangible Assets000000000000000275K448K622K795K968K1.93M2.49M3.4M3.88M0
Long-Term Investments22.17M00000014.82M44.83M13.92M324.8M251.84M279.82M150.05M142.16M114.41M120.39M160.35M83.9M74.78M00000
Other Non-Current Assets60.31M81.63M133.9M111.29M115.48M101.09M85.77M18.07M8.62M34.17M151.56M1.47M000564K003.15M6.33M3.12M2.86M2.83M2.36M66K
Total Assets7.99B4.97B4.24B3.83B3.55B3.64B3.41B2.4B1.57B1.99B1.26B1.39B1.08B420.53M287.52M281.92M393.26M481.38M554.68M493.79M240.01M98.35M66.11M35.18M16.11M
Asset Turnover0.85x0.75x0.53x0.48x0.29x0.23x0.14x0.09x0.05x0.05x0.04x0.03x0.05x0.11x0.23x0.29x0.25x0.21x0.17x0.10x0.11x0.06x0.06x0.01x-
Asset Growth %125.39%17.13%10.71%7.99%-2.66%6.93%42.25%52.09%-21.05%57.96%-8.92%28.43%156.72%46.26%1.99%-28.31%-18.31%-13.21%12.33%105.74%144.04%48.77%87.89%118.38%-
Total Current Liabilities2.06B1.47B1.19B967.79M767.91M695.71M585.27M352.59M179.49M144.25M131.7M62.1M95.33M53.86M48.34M80.99M102.05M110.73M99.45M83.48M22.93M18.48M6.58M3.84M2.67M
Accounts Payable135.4M115.72M88.42M55.52M98.09M73.43M51.97M49.88M59.71M28.36M54.47M16.79M15.11M5.9M4.42M5.8M9.31M12.49M2.59M3.83M4.08M1.98M910K1.51M674K
Days Payables Outstanding38.9262.3799.865.28212.09191.24243.01726.512.09K774.26---------------
Short-Term Debt361.53M0000000000000000003.79M3.22M1.88M790K558K0
Deferred Revenue (Current)23.74M4.84M55.48M102.75M42.1M149.48M127.21M77.82M3.5M41.7M33.54M15.35M23.87M32.7M31.42M62.37M81.62M82.77M79.86M59.25M11.14M10.73M1M333K0
Other Current Liabilities272.04M477.26M421.2M177.16M170.98M130.66M110.75M68.3M40.87M35.81M15.27M12.32M40.03M5.93M950K484K001.56M1.39M00000
Current Ratio2.48x2.76x2.78x3.08x3.51x4.04x4.47x4.87x6.69x12.23x5.10x17.80x7.83x4.72x2.60x1.88x2.49x2.65x4.46x4.77x9.72x4.46x7.33x6.29x5.81x
Quick Ratio2.43x2.71x2.71x2.99x3.34x3.91x4.34x4.71x6.56x12.23x5.10x17.80x7.83x4.72x2.60x1.88x4.71x2.65x4.46x4.77x9.72x4.46x7.33x6.29x5.81x
Cash Conversion Cycle57.3158.6354.62104.98150.46119.54554.8165.58-7.13K----------------
Total Non-Current Liabilities2.33B2.71B2.99B3.08B2.94B2.36B1.81B603.85M93.34M84.05M210.89M59.7M47.99M96.32M105.12M82.93M132.99M192.69M253.1M211.15M15.91M18.09M13.39M58.05M18.08M
Long-Term Debt651.09M1.01B1.02B1.02B1.02B675.7M191.28M030M30M150M000000002.96M5.92M5.52M6.41M1.3M0
Capital Lease Obligations856.9M225.09M229.54M243.1M261.34M281.35M293.04M276.13M00000000000000000
Deferred Tax Liabilities0000000000000000000000000
Other Non-Current Liabilities1.47B1.48B1.73B1.63B1.46B1.25B1.1B9.33M62.88M10.97M11.5M6.73M5.01M2.92M4.25M4.44M3.01M2.8M2.98M4.12M9.99M12.57M6.98M56.74M18.08M
Total Liabilities4.39B4.18B4.17B4.05B3.7B3.06B2.39B956.44M272.84M228.3M342.59M121.8M143.33M150.18M153.47M163.92M235.03M303.42M352.55M294.62M38.83M36.57M19.96M61.89M20.76M
Total Debt1.26B1.28B1.3B1.31B1.32B997.59M521.19M303.82M30M30M150M000000006.76M9.14M7.39M7.2M1.86M0
Net Debt-492.35M-378.86M329.62M492.7M453.85M177.62M24.61M-243.35M-390.15M-615.36M-43.62M-1.28B-881.93M-53.17M-51.41M-70.23M-74.6M-137.47M-191.79M-98.4M-118.82M-8.36M-13.07M-21.33M-15.48M
Debt / Equity0.35x1.62x19.32x--1.70x0.51x0.21x0.02x0.02x0.16x--------0.03x0.05x0.12x0.16x--
Debt / EBITDA1.22x2.29x-----------------------
Net Debt / EBITDA-0.48x-0.68x-----------------------
Interest Coverage3.27x2.28x-1.66x-2.58x-6.23x-4.96x-9.13x------------28.28x-73.07x-----
Total Equity3.6B789.18M67.09M-220.64M-158.22M588.2M1.02B1.44B1.3B1.77B920.22M1.26B936.27M270.35M134.05M118M158.23M177.97M202.13M199.17M201.17M61.78M46.14M-26.71M-4.65M
Equity Growth %3789.09%1076.33%130.41%-39.45%-126.9%-42.12%-29.36%10.5%-26.29%91.96%-27.24%35.08%246.32%101.67%13.61%-25.43%-11.09%-11.95%1.48%-1%225.63%33.89%272.77%-474.84%-
Book Value per Share26.115.860.53-1.77-1.304.978.8413.1712.9419.5110.7515.0612.604.392.672.783.764.274.925.156.312.813.88-28.33-14.02
Total Shareholders' Equity3.6B789.18M67.09M-220.64M-158.22M588.2M1.02B1.44B1.3B1.77B920.22M1.26B936.27M270.35M134.05M118M158.23M177.97M202.13M199.17M201.17M61.78M46.14M-26.71M-4.65M
Common Stock1.34M1.32M1.29M1.26M1.24M1.2M1.16M1.12M1.01M997K859K851K772K637K525K427K423K418K414K408K371K267K208K00
Retained Earnings-4.16B-6.7B-7.29B-7.01B-6.57B-5.44B-4.59B-3.73B-2.84B-2.15B-1.66B-1.25B-956.63M-596.24M-507.01M-401M-343.35M-299.83M-252.24M-225.99M-140.53M-105.92M-63.01M-29.52M-4.49M
Treasury Stock0000000000000000000000000
Accumulated OCI-44.66M-20.1M-34.52M-23.38M-44.65M-33.26M-43.62M-36.52M-33.21M-34.43M-33.44M4.37M48.76M19.72M15.66M-165K714K716K1.19M300K551K-2.6M-3.28M-4.61M-161K
Minority Interest0000000000000000000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetStrained
Cash FlowImproving
Top Statement Risk

Leverage and accumulated deficit

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Equity Rebuilding Despite Persistent Deficit

Based on reported figures, ALNY's equity rose from roughly negative $3M in 2024Q2 to $3.6B in 2026Q3, a shift that reflects retained earnings improvement from a deficit that narrowed from $7.3B to $4.2B over the same period.

The reported equity recovery appears driven primarily by accumulated earnings and capital raised over the period rather than asset growth alone. The accumulated deficit remains very large, which suggests the company is still working through years of losses, and investors should monitor whether earnings quality holds given the earlier analysis of non-operating items inflating net income.

Leverage Falling as Equity Expands

According to reported quarterly figures, ALNY's debt-to-equity ratio compressed from 84.26 in 2024Q3 to 0.35 in 2026Q3, while total debt held steady near $1.3B after an earlier step-down from $2.7B.

The sharp decline in D/E is primarily an equity-denominator effect rather than deleveraging, since absolute debt has been stable at roughly $1.3B since 2025Q4. Debt of this size relative to current cash of $1.8B suggests the company is net cash, but investors should verify the composition of obligations, as financing structures such as royalty-linked liabilities may not be fully captured in headline debt figures.

Cash Cushion Supports Current Liabilities

As reported in financial statements, ALNY held $1.8B in cash in 2026Q3 against a current ratio of 2.48, down from 3.13 in 2026Q1, indicating that short-term obligations are being covered with a narrowing margin of safety.

The current ratio trend suggests current liabilities have grown faster than current assets in recent quarters, which may reflect rising operating payables or deferred obligations tied to commercial expansion. Cash of this magnitude provides a meaningful buffer against near-term shocks, though the falling ratio warrants monitoring as the company scales its commercial and pipeline spending.

Asset-Light Profile With Growing Asset Base

Based on ALNY's reported balance sheet, total assets expanded from $4.0B in 2024Q2 to $8.0B in 2026Q3, while net PP&E grew modestly to $792.9M and goodwill remained at zero.

The absence of goodwill means impairment risk is not a concern, and PP&E at under 10% of total assets is consistent with the outsourced manufacturing model implied by low CapEx intensity. The near doubling of total assets over the period appears to reflect cash accumulation and intangible or receivable growth rather than capital-intensive expansion, so the quality of those non-PP&E assets warrants further investigation.

Deferred Revenue Collapse Signals Lumpy Income

According to reported figures, ALNY's deferred revenue fell from $72.0M in 2024Q3 to just $11.7M in 2026Q3, a decline that may indicate fewer upfront partner payments being carried forward on the balance sheet.

Deferred revenue dropping to low single-digit millions suggests that the headline revenue growth is not being supported by a growing backlog of prepaid obligations, which reduces the visibility that such balances typically provide. This pattern is consistent with the earlier finding that milestone and collaboration income drive much of the quarterly variability, and investors should not extrapolate current revenue levels without adjusting for that lumpiness.

ALNY — Frequently Asked Questions

Quick answers to the most common questions about buying ALNY stock.

What are the total assets of Alnylam Pharmaceuticals, Inc. (ALNY)?

As of 2025, Alnylam Pharmaceuticals, Inc. (ALNY) had total assets of $4.97B including $4.05B in current assets.

How much debt does Alnylam Pharmaceuticals, Inc. (ALNY) have?

Alnylam Pharmaceuticals, Inc. (ALNY) carries total debt of $1.28B, offset by $2.91B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Alnylam Pharmaceuticals, Inc.?

Alnylam Pharmaceuticals, Inc. (ALNY) has total shareholders' equity (book value) of $789.2M ($5.86 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Alnylam Pharmaceuticals, Inc.'s current ratio and liquidity?

Alnylam Pharmaceuticals, Inc. (ALNY) reported a current ratio of 2.76x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.